Validation of a Genetic Signature For Women With Node-Negative Breast Cancer
Publié le
A 70-genetic signature was shown in a single institution to have prognostic value in patients with node-negative breast cancer. The…
Publié le
A 70-genetic signature was shown in a single institution to have prognostic value in patients with node-negative breast cancer. The…
Publié le
Adverse Events coded by IDDI Medical Coding System Two pivotal trials were conducted (one in the US, one in Europe)…
Publié le
A new ophthalmic drug was going to enter a phase II dose-ranging trial in order to determine the dose to…
Publié le
Biomarker Analysis with the Mixed Modelling Methodology Two doses of a therapeutic vaccine were tested simultaneously in a randomized phase II…
Publié le
Meta-Analysis performed with IDDI’s Methodology Skills IDDI has been involved in numerous meta-analyses to directly or indirectly support new drug applications….
Publié le
Surrogate endpoint for overall survival We managed to prove, using data from a randomized trial comparing Ceplene + IL-2 to…
Publié le
Free Webinar on Biomarker-Based Clinical Trial Designs The webinar on biomarker-based clinical trial designs reviewed of the recently proposed-designs, including adaptive…
Publié le
IDDI organized its first free live webinar on STATISTICAL VALIDATION OF BIOMARKERS WATCH RECORDED WEBINAR TO ACCESS THE PRESENTATION OF THIS…
Publié le
IDDI organized its second free live webinar on DEVELOPMENT AND VALIDATION OF CLINICALLY USEFUL GENE SIGNATURES. This webinar reviewed statistical issues…
Publié le
IDDI organized a webinar on Operational Aspects of Data Monitoring Committees. The webinar explored best practices that have emerged during this…